Health disparities in chronic liver disease
- PMID: 35993341
- PMCID: PMC10026975
- DOI: 10.1002/hep.32743
Health disparities in chronic liver disease
Abstract
The syndemic of hazardous alcohol consumption, opioid use, and obesity has led to important changes in liver disease epidemiology that have exacerbated health disparities. Health disparities occur when plausibly avoidable health differences are experienced by socially disadvantaged populations. Highlighting health disparities, their sources, and consequences in chronic liver disease is fundamental to improving liver health outcomes. There have been large increases in alcohol use disorder in women, racial and ethnic minorities, and those experiencing poverty in the context of poor access to alcohol treatment, leading to increasing rates of alcohol-associated liver diseases. Rising rates of NAFLD and associated fibrosis have been observed in Hispanic persons, women aged > 50, and individuals experiencing food insecurity. Access to viral hepatitis screening and linkage to treatment are suboptimal for racial and ethnic minorities and individuals who are uninsured or underinsured, resulting in greater liver-related mortality and later-stage diagnoses of HCC. Data from more diverse cohorts on autoimmune and cholestatic liver diseases are lacking, supporting the need to study the contemporary epidemiology of these disorders in greater detail. Herein, we review the existing literature on racial and ethnic, gender, and socioeconomic disparities in chronic liver diseases using a social determinants of health framework to better understand how social and structural factors cause health disparities and affect chronic liver disease outcomes. We also propose potential solutions to eliminate disparities, outlining health-policy, health-system, community, and individual solutions to promote equity and improve health outcomes.
Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc.
Conflict of interest statement
Marina Serper consults for Gilead. Norah Terrault consults for EXIGO Management Consultants LLC, ENYO, Entourage Pharma, PPD Pharma‐Moderna, Dova Pharmaceuticals, Intercept, and Moderna. She received grants from Gilead, Glaxo‐Smith‐Kline, Roche‐Genentech, Allergan Pharmaceuticals, DURECT Corp, and Helio Health. She provides continuing medical education for Focus Medical Communications.
Figures





Similar articles
-
Racial/ethnic disparities in alcohol-related problems: differences by gender and level of heavy drinking.Alcohol Clin Exp Res. 2014 Jun;38(6):1662-70. doi: 10.1111/acer.12398. Epub 2014 Apr 14. Alcohol Clin Exp Res. 2014. PMID: 24730475 Free PMC article.
-
Actionable Solutions to Achieve Health Equity in Chronic Liver Disease.Clin Gastroenterol Hepatol. 2023 Jul;21(8):1992-2000. doi: 10.1016/j.cgh.2023.03.043. Epub 2023 Apr 13. Clin Gastroenterol Hepatol. 2023. PMID: 37061105 Free PMC article. Review.
-
Racial-ethnic disparities in stroke care: the American experience: a statement for healthcare professionals from the American Heart Association/American Stroke Association.Stroke. 2011 Jul;42(7):2091-116. doi: 10.1161/STR.0b013e3182213e24. Epub 2011 May 26. Stroke. 2011. PMID: 21617147
-
Racial Disparities in Payment Source of Opioid Use Disorder Treatment among Non-Incarcerated Justice-Involved Adults in the United States.J Ment Health Policy Econ. 2020 Mar 1;23(1):19-25. J Ment Health Policy Econ. 2020. PMID: 32458814
-
We Are Not Immune: Racial and Ethnic Disparities in Autoimmune Liver Diseases.Hepatology. 2021 Nov;74(5):2876-2887. doi: 10.1002/hep.31985. Epub 2021 Aug 10. Hepatology. 2021. PMID: 34056734 Review.
Cited by
-
Ameliorative effects of sildenafil against carbon tetrachloride induced hepatic fibrosis in rat model through downregulation of osteopontin gene expression.Sci Rep. 2024 Jul 23;14(1):16902. doi: 10.1038/s41598-024-67305-1. Sci Rep. 2024. PMID: 39043726 Free PMC article.
-
Uncoupling hepatic insulin resistance - hepatic inflammation to improve insulin sensitivity and to prevent impaired metabolism-associated fatty liver disease in type 2 diabetes.Front Endocrinol (Lausanne). 2023 Jun 15;14:1193373. doi: 10.3389/fendo.2023.1193373. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 37396181 Free PMC article. Review.
-
Reduction of the Risk of Hepatocellular Carcinoma over Time Using Direct-Acting Antivirals: A Propensity Score Analysis of a Real-Life Cohort (PITER HCV).Viruses. 2024 Apr 26;16(5):682. doi: 10.3390/v16050682. Viruses. 2024. PMID: 38793565 Free PMC article.
-
Material economic hardships are associated with adverse 1-year outcomes after pediatric liver transplantation: Prospective cohort results from the multicenter SOCIAL-Tx Study.Liver Transpl. 2025 Aug 1;31(8):1042-1052. doi: 10.1097/LVT.0000000000000554. Epub 2024 Dec 16. Liver Transpl. 2025. PMID: 39692470
-
Differences in liver and mortality outcomes of non-alcoholic fatty liver disease by race and ethnicity: A longitudinal real-world study.Clin Mol Hepatol. 2023 Oct;29(4):1002-1012. doi: 10.3350/cmh.2023.0205. Epub 2023 Sep 11. Clin Mol Hepatol. 2023. PMID: 37691484 Free PMC article.
References
-
- Alcaraz KI, Weidt TL, Daniels EC, Yabroff KR, Guerra CE, Wender RC. Understanding and addressing social determinants to advance cancer health equity in the United States: a blueprint for practice, research, and policy. CA Cancer J Clin. 2020;70:31–46. - PubMed
-
- Solar O, Irwin A. A conceptual framework for action on the social determinants of health. Geneva, Switzerland: World Health Organization; 2010.
-
- Castrucci BC, Auerbach J. Meeting individual social needs falls short of addressing social determinants of health. Health Affairs Blog. 2019. 10.1377/forefront.20190115.234942 - DOI
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical